NASDAQ:CMPS COMPASS Pathways (CMPS) Stock Price, News & Analysis $8.03 +0.57 (+7.64%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$7.48▼$8.1350-Day Range$5.81▼$8.0352-Week Range$5.01▼$12.75Volume518,027 shsAverage Volume557,815 shsMarket Capitalization$549.09 millionP/E RatioN/ADividend YieldN/APrice Target$43.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get COMPASS Pathways alerts: Email Address COMPASS Pathways MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside439.6% Upside$43.33 Price TargetShort InterestBearish6.39% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.36Based on 10 Articles This WeekInsider TradingSelling Shares$79,758 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.24) to ($2.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.37 out of 5 starsMedical Sector750th out of 936 stocksPharmaceutical Preparations Industry350th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingCOMPASS Pathways has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCOMPASS Pathways has only been the subject of 3 research reports in the past 90 days.Read more about COMPASS Pathways' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted6.39% of the outstanding shares of COMPASS Pathways have been sold short.Short Interest Ratio / Days to CoverCOMPASS Pathways has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.Change versus previous monthShort interest in COMPASS Pathways has recently increased by 2.10%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCOMPASS Pathways does not currently pay a dividend.Dividend GrowthCOMPASS Pathways does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CMPS. Previous Next 2.4 News and Social Media Coverage News SentimentCOMPASS Pathways has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for COMPASS Pathways this week, compared to 2 articles on an average week.Search InterestOnly 7 people have searched for CMPS on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.MarketBeat Follows9 people have added COMPASS Pathways to their MarketBeat watchlist in the last 30 days. This is an increase of 13% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, COMPASS Pathways insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $79,758.00 in company stock.Percentage Held by InsidersOnly 4.25% of the stock of COMPASS Pathways is held by insiders.Percentage Held by Institutions46.19% of the stock of COMPASS Pathways is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about COMPASS Pathways' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for COMPASS Pathways are expected to grow in the coming year, from ($2.24) to ($2.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of COMPASS Pathways is -3.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of COMPASS Pathways is -3.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCOMPASS Pathways has a P/B Ratio of 2.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about COMPASS Pathways' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.In answer to this issue, we have released a Special Report to the public. About COMPASS Pathways Stock (NASDAQ:CMPS)COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Read More CMPS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CMPS Stock News HeadlinesJuly 26 at 1:12 AM | americanbankingnews.comCOMPASS Pathways plc (NASDAQ:CMPS) Receives $43.33 Average PT from BrokeragesJuly 25 at 9:20 AM | americanbankingnews.comCOMPASS Pathways (NASDAQ:CMPS) Shares Gap Up to $7.43July 26, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.July 24 at 12:11 PM | msn.comRBC Capital Initiates Coverage of COMPASS Pathways plc - Depositary Receipt () (CMPS) with Outperform RecommendationJuly 24 at 11:51 AM | americanbankingnews.comCOMPASS Pathways (NASDAQ:CMPS) Coverage Initiated by Analysts at Royal Bank of CanadaJuly 24 at 7:01 AM | globenewswire.comCompass Pathways to announce second quarter financial results on August 1, 2024July 8, 2024 | seekingalpha.comCompass Pathways: Buy It For Its Promising Psychedelic Mental Health TherapiesJuly 8, 2024 | investorplace.com3 Next-Gen Drug Stocks Exploring Psychedelic FrontiersJuly 26, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.July 2, 2024 | investorplace.com3 Psychedelic Stocks to Buy on the Dip: Summer 2024June 26, 2024 | globenewswire.comCompass Pathways appoints Lori Englebert as Chief Commercial OfficerJune 24, 2024 | globenewswire.comCompass Pathways to participate in upcoming H.C. Wainwright 5th Annual Neuro Perspectives Virtual ConferenceJune 12, 2024 | fool.comShould You Buy the Dip on Compass Pathways Stock?May 21, 2024 | fool.comThese 2 Catalysts Could Soon Send Compass Pathways Stock SoaringMay 13, 2024 | finance.yahoo.comCOMPASS Pathways plc (NASDAQ:CMPS) Q1 2024 Earnings Call TranscriptMay 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for COMPASS Pathways Amid Strong Financials and Promising Clinical TrialsMay 9, 2024 | fool.comCompass Pathways Plc (CMPS) Q1 2024 Earnings Call TranscriptMay 8, 2024 | msn.comCMPS Stock Earnings: Compass Pathways Misses EPS for Q1 2024See More Headlines Receive CMPS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for COMPASS Pathways and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Confirmed)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CMPS CUSIPN/A CIK1816590 Webwww.compasspathways.com Phone716-676-6461FaxN/AEmployees120Year Founded2016Price Target and Rating Average Stock Price Target$43.33 High Stock Price Target$120.00 Low Stock Price Target$16.00 Potential Upside/Downside+445.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-118,460,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-57.24% Return on Assets-47.33% Debt Debt-to-Equity Ratio0.12 Current Ratio15.23 Quick Ratio15.23 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.65 per share Price / Book2.18Miscellaneous Outstanding Shares68,380,000Free Float65,475,000Market Cap$543.62 million OptionableOptionable Beta2.27 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Kabir Kumar Nath M.A. (Age 60)M.B.A., CEO & Director Comp: $1.31MMr. Matthew Allen Owens (Age 47)General Counsel & Chief Legal Officer Comp: $684.51kDr. Guy Goodwin (Age 76)Chief Medical Officer Comp: $567kMs. Teri Loxam M.B.A. (Age 51)CFO, Principal Financial Officer & Principal Accounting Officer Dr. Greg Ryslik Ph.D.Chief Technology OfficerMr. Stephen D. SchultzSenior Vice President of Investor RelationsMr. Christopher WilliamsChief Communications OfficerMs. Anne BenedictChief People OfficerMr. Lars Christian Wilde (Age 39)Senior Advisor Mr. Trevor MillChief Development OfficerMore ExecutivesKey CompetitorsMacroGenicsNASDAQ:MGNXSage TherapeuticsNASDAQ:SAGETravere TherapeuticsNASDAQ:TVTXRepare TherapeuticsNASDAQ:RPTXPMV PharmaceuticalsNASDAQ:PMVPView All CompetitorsInsiders & InstitutionsARK Investment Management LLCSold 60,723 shares on 7/26/2024Ownership: 3.072%Hennion & Walsh Asset Management Inc.Bought 109,989 shares on 7/20/2024Ownership: 0.161%Sumitomo Mitsui Trust Holdings Inc.Sold 38,745 shares on 7/19/2024Ownership: 0.422%Blue Trust Inc.Bought 13,368 shares on 7/18/2024Ownership: 0.020%Virtu Financial LLCBought 24,189 shares on 5/20/2024Ownership: 0.035%View All Insider TransactionsView All Institutional Transactions CMPS Stock Analysis - Frequently Asked Questions How have CMPS shares performed this year? COMPASS Pathways' stock was trading at $8.75 at the start of the year. Since then, CMPS stock has decreased by 8.2% and is now trading at $8.03. View the best growth stocks for 2024 here. How were COMPASS Pathways' earnings last quarter? COMPASS Pathways plc (NASDAQ:CMPS) released its quarterly earnings results on Wednesday, May, 8th. The company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.52) by $0.03. When did COMPASS Pathways IPO? COMPASS Pathways (CMPS) raised $100 million in an initial public offering on Friday, September 18th 2020. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Cowen, Evercore ISI and Berenberg acted as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are COMPASS Pathways' major shareholders? COMPASS Pathways' top institutional investors include ARK Investment Management LLC (3.07%), Sumitomo Mitsui Trust Holdings Inc. (0.42%), Hennion & Walsh Asset Management Inc. (0.16%) and Blue Trust Inc. (0.02%). Insiders that own company stock include Ekaterina Malievskaia, George Jay Goldsmith and David Y Norton. View institutional ownership trends. How do I buy shares of COMPASS Pathways? Shares of CMPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of COMPASS Pathways own? Based on aggregate information from My MarketBeat watchlists, some other companies that COMPASS Pathways investors own include Nikola (NKLA), Vaxart (VXRT), Beyond Meat (BYND), Evofem Biosciences (EVFM), GrowGeneration (GRWG), McDonald's (MCD) and Plug Power (PLUG). This page (NASDAQ:CMPS) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding COMPASS Pathways plc Please log in to your account or sign up in order to add this asset to your watchlist. Share COMPASS Pathways With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
